Intiva Token

A decentralized medical credentialing system, built to save billions in outdated admin processes.

About Intiva Token

Intiva Health aims to create a platform for health-care professionals that will simplify administrative tasks and increase efficiency. Facilities and medical groups (FMGs) will be able simplify the credential/recruitment process of licensed medical professionals (LMPs) while maintaining compliance. NTVA tokens will be used as a means of exchange on the Intiva Health platform and for access to data and marketing tools.

Token Sale Use of Blockchain

Product

1.8
Product
Readiness

Is the product ready for use? Is there a working prototype or MVP? How long until it is operational?

2.0
N/A
2 - Proof of concept or test platform.
Appeal

How appealing is the product? How good or necessary is it? Does it have a distinct edge?

2.0
N/A
2 - Meh, okay.
Target User Base

Is it mass market or niche?

2.0
N/A
2 - Small audience / niche market.
Competition

Are there many other similar solutions or is this one of just a few, or even one of a kind?

1.0
N/A
1 - Many / much better competitors.
Innovation

How innovative or inventive is the product, either conceptually or technologically?

2.0
N/A
2 - Some, but nothing outstanding.

Product

Intiva Health’s target user base is comprised of medical professionals. There is a fair number of blockchain-related projects that aim to target the health-care sector. One of the services provided through the Intiva Health platform is ReadyDoc, which allows instantaneous verification of a provider’s work history using Hashgraph. The service allows LMPs and FMGs to easily manage and share their credentials. The GitHub page does not contain any publicly available repositories.

Product Whitepaper

Use of Blockchain

2.8
Use of Blockchain
Blockchain Development

Is blockchain technology essential? Does it make the solution significantly different and better?

3.0
N/A
3 - Automation; making something easier to do.
Disruptive Blockchain Advantage

How disruptive is the introduction of blockchain technology into the product's market space?

4.0
N/A
4 - Generally disruptive.
Need for a Custom Token (vs. BTC or ETH)

Is the token essential or could it be done just as well or better with fiat or Bitcoin?

2.0
N/A
2 - Some, mainly network effect.
System Decentralization (besides token)

How decentralized is the system architecture other than the token (e.g., data collection, storage, access, and use, or decision making processes, etc.)?

3.0
N/A
3 - Hybrid; decentralized as far as circumstances allow.
Contribution to Blockchain Ecosystem

How compelling is the solution's contribution to the evolution of blockchain infrastructure and economy?

2.0
N/A
2 - Meh, okay.

Use of Blockchain

NTVA is an ERC20 compliant token used as a means of exchange and for access to services provided by the platform. The Intiva Health platform will use Hashgraph technology. It is stated that documents will be encrypted and distributed across the node network. Further detail is not provided. The strategy that Intiva Health plans to use with regard to network operation is unclear. The system of governance is also not discussed. Thus, the need to create a custom token (beyond funding purposes) is not clearly discussed.

Use of Blockchain Roadmap

Whitepaper

2.8
Whitepaper
Comprehensiveness

Does it cover the full scope of the problem and solution?

3.0
N/A
3 - Covers most key issues; a few holes.
Readability

Is it easy enough to understand?

3.0
N/A
3 - Readable, takes some time.
Transparency

Does it candidly describe and disclose where the project now stands, how much exists and how much still needs to be done, etc.?

3.0
N/A
3 - Basic honesty with some hype.
Business Plan Presentation

Does it contain a viable, comprehensive business plan?

3.0
N/A
3 - More information required.
Technology Presentation

Does it present a well thought out technological architecture? Does it address implementational challenges?

2.0
N/A
2 - Missing critical information.

Whitepaper

The whitepaper is 48 pages in length. The technology plan is presented with fairly low levels of detail. Technical aspects of the platform are discussed at a layman level. For example, Hashgraph is discussed in the document, but in a fairly generic and simplistic manner focusing mainly on the benefits of Hashgraph technology rather than on how it will be implemented in the platform specifically. The business plan is presented with low levels of detail. There is a section that addresses the business model within approximately 2 pages. The business model consists of obtaining partnerships, receiving grants, and selling products and services on the Intiva health platform (collecting up to 50% of the fees). The marketing strategy primarily consists of sponsored alerts (which give access to qualified leads) and referrals. There is a lack of discussion with regard to Intiva Health’s competitors. Overall, the whitepaper lacks detail.

Whitepaper Compliance

Roadmap

2.2
Roadmap
Concreteness

Is there a concrete and practical development plan (vs. just a conceptual vision)?

2.0
N/A
2 - Vague, noncommittal.
Feasibility

Is the development plan realistic? Is it based on reasonable goals and timelines?

3.0
N/A
3 - Optimistic.
Vision

Is there a larger, long-term vision?

2.0
N/A
2 - Riding the current wave.
Dependencies (services or capabilities)

How available, operational, or trusted are the other systems or capabilities on which the project relies?

2.0
N/A
2 - Not fully available or trustworthy.
Current Position

Where is the project now, relative to its vision and plans?

2.0
N/A
2 - Critical obstacles ahead.

Roadmap

The roadmap in the Intiva Health whitepaper spans from May 2017 to January 2019 (and beyond). Development is divided into three groups of milestones: Intiva with Hashgraph, the Platform, and NTVA/share offering. Milestones are presented with low levels of detail. For example, the first 5 milestones presented consist of : Safe, Intiva Careers, CME, Alerts, and CV Builder. It is stated that by August 2018, LMPs will be able to use NTVA tokens.

Roadmap Company and Team

Compliance

2.6
Compliance
Token Utility (value through usage)

How much use is there for the token itself (regardless of its value as an investment vehicle)?

2.0
N/A
2 - Minimal or contrived.
Token as Security (tradable instrument)

How valuable is the token as an investment vehicle or financial instrument?

2.0
N/A
2 - Primarily, with few additional rights.
Token/Smart-Contract Readiness

Is the blockchain infrastructure of the project ready for use? Is there a working prototype or MVP? How long until it is operational?

1.0
N/A
1 - Nothing yet, just an idea.
Attention to Compliance Issues

How much attention is given to compliance (via token and ecosystem design, token sale participation, etc.)? Is this issue addressed directly and coherently?

4.0
N/A
4 - Specific, detailed.
Legal Review/Risk Assessment

What kind of legal documentation (reviews or agreements) and risk assessment are provided?

4.0
N/A
4 - Professional.

Compliance

The document begins with the organization’s due diligence with respect to the whitepaper. Further discussion is provided with respect to the token and the token sale throughout the document. Overall, the language is fairly professional and the content regarding the legal aspects of the platform span approximately 10 pages. Company shares are also planned for the organization and the corresponding Offering Memorandum “will be prepared in connection with a private offering to Accredited Investors in the United States, individuals who will be required to verify their Accredited Investor status through a questionnaire and other necessary documentation”. A table is presented that outlines share prices. With respect to company shares, the sale in the United States will be pursuant to Rule 506(c) of Regulation D of the Securities Act of 1933. It is stated that “the issuance and sale of the Company Shares have not been registered under the Securities Act or any other applicable securities law”. KYC will be used for the token sale. The sector that Intiva Health is targeting has fairly high levels of regulatory friction. However much of the legal considerations presented in the whitepaper pertain to the whitepaper and the token sale.

Compliance Token Sale

Company and Team

2.0
Company and Team
Company Stage and Foundation

Is the company already established? Has it raised funds before? Is it mature?

2.0
N/A
2 - Initial stages of formation.
Background of Lead Team Members

Do we know who they are? Do they have LinkedIn profiles? Do they have solid, relevant backgrounds?

3.0
N/A
3 - Minimally sufficient.
Team Assembly and Commitment

Is a solid, fully committed core team in place? Do they have online (e.g. LinkedIn) profiles showing sufficient relevant experience? Is their participation transparent?

2.0
N/A
2 - Lacking in key areas.
Team Skill Set Relevance

Does the amount of talent and skill in each area seem to fit the project requirements?

2.0
N/A
2 - Lacking or inconsistent.
Team Skill Set Balance

Is the team well-rounded (biz/tech/blockchain)? Is there sufficient talent and skill in all areas of required development?

1.0
N/A
1 - Severely skewed.

Company and Team

The executive team of 4 individuals is listed on the Intiva Health website, along with their profile pictures, job titles and links to social media profiles. There is an additional two-member product development team listed in the whitepaper, but one of these members is listed as an advisor on the website. The LinkedIn profile of the technical lead/advisor shows the individual to be concurrently involved with other projects/organizations, and does not list Intiva Health. Thus, the level of technical expertise and commitment to the project is questionable, especially considering that some of the lead team members are also concurrently involved with other projects/organizations.

Company and Team Product

Token Sale

2.2
Token Sale
Raise Amount Max

Is there a clear cap? Is the maximum raise amount modestly sufficient (as opposed to either greedy or insufficient)?

2.0
N/A
2 - Somewhat greedy or unrelated to plans.
Raise Amount Min

Is the minimum raise reasonable considering the development plan? Are there raise-amount dependent milestones?

1.0
N/A
1 - None or nonsensical.
Fund Allocation

Is fund distribution and allocation reasonable and justified?

3.0
N/A
3 - Rough estimates, but sensible.
Token Allocation

Is the ratio of tokens sold to those kept reasonable? Does it prevent the company from having too much control?

3.0
N/A
3 - Sufficient company/community interest balance.
Media Presence and Following

Is the sale being talked about in Reddit, Bitcointalk, Social Media, Medium, etc.? Is information available and accessible? Is there interest?

2.0
N/A
2 - Minor exposure and interest, or ambivalent reception.

Token Sale

The total number of NTVA tokens is 1 billion (12% is for the token sale, 12% is for the pre-sale, 35% for the LMP incentive fund, 30% is for the FMG fund, 5.5% is for the reserve fund, 3% is for miscellaneous expenses, and 2.5% is for staff incentives). The allocation of funds is described with moderate detail (35% is for marketing, 20% is for the reserve fund, 15% is for sales, 10% is for development, 10% is for employee incentives and hiring, and 10% is for administrative expenses). The soft cap is unspecified and the hard cap is $12MM USD, where 1 NTVA = $0.50 USD.

Product

Intiva Health’s target user base is comprised of medical professionals. There is a fair number of blockchain-related projects that aim to target the health-care sector. One of the services provided through the Intiva Health platform is ReadyDoc, which allows instantaneous verification of a provider’s work history using Hashgraph. The service allows LMPs and FMGs to easily manage and share their credentials. The GitHub page does not contain any publicly available repositories.

Category Breakdown
Readiness

Is the product ready for use? Is there a working prototype or MVP? How long until it is operational?

2.0
N/A
2 - Proof of concept or test platform.
Appeal

How appealing is the product? How good or necessary is it? Does it have a distinct edge?

2.0
N/A
2 - Meh, okay.
Target User Base

Is it mass market or niche?

2.0
N/A
2 - Small audience / niche market.
Competition

Are there many other similar solutions or is this one of just a few, or even one of a kind?

1.0
N/A
1 - Many / much better competitors.
Innovation

How innovative or inventive is the product, either conceptually or technologically?

2.0
N/A
2 - Some, but nothing outstanding.
Product Score:
1.8

Use of Blockchain

NTVA is an ERC20 compliant token used as a means of exchange and for access to services provided by the platform. The Intiva Health platform will use Hashgraph technology. It is stated that documents will be encrypted and distributed across the node network. Further detail is not provided. The strategy that Intiva Health plans to use with regard to network operation is unclear. The system of governance is also not discussed. Thus, the need to create a custom token (beyond funding purposes) is not clearly discussed.

Category Breakdown
Blockchain Development

Is blockchain technology essential? Does it make the solution significantly different and better?

3.0
N/A
3 - Automation; making something easier to do.
Disruptive Blockchain Advantage

How disruptive is the introduction of blockchain technology into the product's market space?

4.0
N/A
4 - Generally disruptive.
Need for a Custom Token (vs. BTC or ETH)

Is the token essential or could it be done just as well or better with fiat or Bitcoin?

2.0
N/A
2 - Some, mainly network effect.
System Decentralization (besides token)

How decentralized is the system architecture other than the token (e.g., data collection, storage, access, and use, or decision making processes, etc.)?

3.0
N/A
3 - Hybrid; decentralized as far as circumstances allow.
Contribution to Blockchain Ecosystem

How compelling is the solution's contribution to the evolution of blockchain infrastructure and economy?

2.0
N/A
2 - Meh, okay.
Use of Blockchain Score:
2.8

Whitepaper

The whitepaper is 48 pages in length. The technology plan is presented with fairly low levels of detail. Technical aspects of the platform are discussed at a layman level. For example, Hashgraph is discussed in the document, but in a fairly generic and simplistic manner focusing mainly on the benefits of Hashgraph technology rather than on how it will be implemented in the platform specifically. The business plan is presented with low levels of detail. There is a section that addresses the business model within approximately 2 pages. The business model consists of obtaining partnerships, receiving grants, and selling products and services on the Intiva health platform (collecting up to 50% of the fees). The marketing strategy primarily consists of sponsored alerts (which give access to qualified leads) and referrals. There is a lack of discussion with regard to Intiva Health’s competitors. Overall, the whitepaper lacks detail.

Category Breakdown
Comprehensiveness

Does it cover the full scope of the problem and solution?

3.0
N/A
3 - Covers most key issues; a few holes.
Readability

Is it easy enough to understand?

3.0
N/A
3 - Readable, takes some time.
Transparency

Does it candidly describe and disclose where the project now stands, how much exists and how much still needs to be done, etc.?

3.0
N/A
3 - Basic honesty with some hype.
Business Plan Presentation

Does it contain a viable, comprehensive business plan?

3.0
N/A
3 - More information required.
Technology Presentation

Does it present a well thought out technological architecture? Does it address implementational challenges?

2.0
N/A
2 - Missing critical information.
Whitepaper Score:
2.8

Roadmap

The roadmap in the Intiva Health whitepaper spans from May 2017 to January 2019 (and beyond). Development is divided into three groups of milestones: Intiva with Hashgraph, the Platform, and NTVA/share offering. Milestones are presented with low levels of detail. For example, the first 5 milestones presented consist of : Safe, Intiva Careers, CME, Alerts, and CV Builder. It is stated that by August 2018, LMPs will be able to use NTVA tokens.

Category Breakdown
Concreteness

Is there a concrete and practical development plan (vs. just a conceptual vision)?

2.0
N/A
2 - Vague, noncommittal.
Feasibility

Is the development plan realistic? Is it based on reasonable goals and timelines?

3.0
N/A
3 - Optimistic.
Vision

Is there a larger, long-term vision?

2.0
N/A
2 - Riding the current wave.
Dependencies (services or capabilities)

How available, operational, or trusted are the other systems or capabilities on which the project relies?

2.0
N/A
2 - Not fully available or trustworthy.
Current Position

Where is the project now, relative to its vision and plans?

2.0
N/A
2 - Critical obstacles ahead.
Roadmap Score:
2.2

Compliance

The document begins with the organization’s due diligence with respect to the whitepaper. Further discussion is provided with respect to the token and the token sale throughout the document. Overall, the language is fairly professional and the content regarding the legal aspects of the platform span approximately 10 pages. Company shares are also planned for the organization and the corresponding Offering Memorandum “will be prepared in connection with a private offering to Accredited Investors in the United States, individuals who will be required to verify their Accredited Investor status through a questionnaire and other necessary documentation”. A table is presented that outlines share prices. With respect to company shares, the sale in the United States will be pursuant to Rule 506(c) of Regulation D of the Securities Act of 1933. It is stated that “the issuance and sale of the Company Shares have not been registered under the Securities Act or any other applicable securities law”. KYC will be used for the token sale. The sector that Intiva Health is targeting has fairly high levels of regulatory friction. However much of the legal considerations presented in the whitepaper pertain to the whitepaper and the token sale.

Category Breakdown
Token Utility (value through usage)

How much use is there for the token itself (regardless of its value as an investment vehicle)?

2.0
N/A
2 - Minimal or contrived.
Token as Security (tradable instrument)

How valuable is the token as an investment vehicle or financial instrument?

2.0
N/A
2 - Primarily, with few additional rights.
Token/Smart-Contract Readiness

Is the blockchain infrastructure of the project ready for use? Is there a working prototype or MVP? How long until it is operational?

1.0
N/A
1 - Nothing yet, just an idea.
Attention to Compliance Issues

How much attention is given to compliance (via token and ecosystem design, token sale participation, etc.)? Is this issue addressed directly and coherently?

4.0
N/A
4 - Specific, detailed.
Legal Review/Risk Assessment

What kind of legal documentation (reviews or agreements) and risk assessment are provided?

4.0
N/A
4 - Professional.
Compliance Score:
2.6

Company and Team

The executive team of 4 individuals is listed on the Intiva Health website, along with their profile pictures, job titles and links to social media profiles. There is an additional two-member product development team listed in the whitepaper, but one of these members is listed as an advisor on the website. The LinkedIn profile of the technical lead/advisor shows the individual to be concurrently involved with other projects/organizations, and does not list Intiva Health. Thus, the level of technical expertise and commitment to the project is questionable, especially considering that some of the lead team members are also concurrently involved with other projects/organizations.

Category Breakdown
Company Stage and Foundation

Is the company already established? Has it raised funds before? Is it mature?

2.0
N/A
2 - Initial stages of formation.
Background of Lead Team Members

Do we know who they are? Do they have LinkedIn profiles? Do they have solid, relevant backgrounds?

3.0
N/A
3 - Minimally sufficient.
Team Assembly and Commitment

Is a solid, fully committed core team in place? Do they have online (e.g. LinkedIn) profiles showing sufficient relevant experience? Is their participation transparent?

2.0
N/A
2 - Lacking in key areas.
Team Skill Set Relevance

Does the amount of talent and skill in each area seem to fit the project requirements?

2.0
N/A
2 - Lacking or inconsistent.
Team Skill Set Balance

Is the team well-rounded (biz/tech/blockchain)? Is there sufficient talent and skill in all areas of required development?

1.0
N/A
1 - Severely skewed.
Company and Team Score:
2.0

Token Sale

The total number of NTVA tokens is 1 billion (12% is for the token sale, 12% is for the pre-sale, 35% for the LMP incentive fund, 30% is for the FMG fund, 5.5% is for the reserve fund, 3% is for miscellaneous expenses, and 2.5% is for staff incentives). The allocation of funds is described with moderate detail (35% is for marketing, 20% is for the reserve fund, 15% is for sales, 10% is for development, 10% is for employee incentives and hiring, and 10% is for administrative expenses). The soft cap is unspecified and the hard cap is $12MM USD, where 1 NTVA = $0.50 USD.

Category Breakdown
Raise Amount Max

Is there a clear cap? Is the maximum raise amount modestly sufficient (as opposed to either greedy or insufficient)?

2.0
N/A
2 - Somewhat greedy or unrelated to plans.
Raise Amount Min

Is the minimum raise reasonable considering the development plan? Are there raise-amount dependent milestones?

1.0
N/A
1 - None or nonsensical.
Fund Allocation

Is fund distribution and allocation reasonable and justified?

3.0
N/A
3 - Rough estimates, but sensible.
Token Allocation

Is the ratio of tokens sold to those kept reasonable? Does it prevent the company from having too much control?

3.0
N/A
3 - Sufficient company/community interest balance.
Media Presence and Following

Is the sale being talked about in Reddit, Bitcointalk, Social Media, Medium, etc.? Is information available and accessible? Is there interest?

2.0
N/A
2 - Minor exposure and interest, or ambivalent reception.
Token Sale Score:
2.2

Use this code to share the ratings on your website